Secondary Progressive Multiple Sclerosis (SPMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Secondary progressive multiple sclerosis (SPMS) represents the phase of the disease that follows the initial relapsing-remitting stage, characterized by a gradual decline in neurological function independent of relapses. While SPMS is typically viewed as a distinct subtype of multiple sclerosis, it shares some common pathological features and disease mechanisms with the relapsing-remitting form. The transition from relapsing-remitting MS to SPMS poses clinical challenges due to the variable nature of the disease, vague progression patterns, and the lack of established biomarkers and diagnostic tools. The primary treatment objective for SPMS is universally recognized as halting disease progression and preventing symptom exacerbation. Managing SPMS involves both pharmacological interventions, including drugs designed for relapsing cases and symptom-relief medications, as well as non-pharmacological approaches such as rehabilitation and physiotherapy to address symptoms like fatigue, cognitive impairment, and spasticity.

·       In the United States, SPMS is estimated to affect approximately 19% to 25% of all individuals diagnosed with multiple sclerosis, with a prevalence ranging from 39 to 47 cases per 100,000 in the population.

 

Thelansis’s “Secondary Progressive Multiple Sclerosis (SPMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Secondary Progressive Multiple Sclerosis (SPMS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Secondary Progressive Multiple Sclerosis (SPMS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Secondary Progressive Multiple Sclerosis (SPMS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Secondary Progressive Multiple Sclerosis (SPMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive Multiple Sclerosis (SPMS) market outlook, Secondary Progressive Multiple Sclerosis (SPMS) competitive landscape, Secondary Progressive Multiple Sclerosis (SPMS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)